Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Allergy Therapeutics plc    AGY   GB00B02LCQ05


Delayed Quote. Delayed London Stock Exchange - 01/19 11:35:18 am
20 GBX   +2.56%
01/14ALLERGY THERAPEUTICS : Half Year Trading Update 2021 and Notice of Results
2020ALLERGY THERAPEUTICS : 2020 AGM Poll Vote Results
2020ALLERGY THERAPEUTICS : Notice of Meeting
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Allergy Therapeutics :  Allergy Therapeutics plc Preliminary Results for the year ended 30 June 2020

09/23/2020 | 07:01am EST

 Allergy Therapeutics plc

(“Allergy Therapeutics”, “ATL” or the “Group”)

Preliminary Results for the year ended 30 June 2020

  • Record level of pre R&D operating profit supported by robust sales and operational efficiency
  • Strong cash position with Grass MATA MPL Phase III programme and initial Phase I peanut trial fully funded
  • Exclusive licencing agreement signed for further virus like particle(VLP) candidates


23 September 2020Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announces its preliminary results for the year ended 30 June 2020.

Financial Highlights

  • 7% revenue growth at constant rate* and 6% at reported rate to £78.2m (2019: £73.7m)
  • 25% increase in pre-R&D operating profit to £14.2m (2019: £11.3m) as a result of sales growth and lower overhead cost growth
  • Strong cash balance of £37.0m at 30 June 2020 (2019: £27.4m)
  • Net profit of £7.1m for the year including one-off, legal settlement of £3.2m (2019: Net profit of £3.5m)

Operating Highlights (including post period)

  • Good growth across all key products in the portfolio with further incremental increase in market share in European business
  • Exploratory field study for Grass MATA MPL will begin in Q4 2020, moving on to the second stage Phase III trial in H2 2022 to improve outcome and mitigate risk
  • Licence agreement signed with Saiba and DeepVax, VLP partner to explore new therapeutic areas, including solid cancer tumours and asthma
  • Signed exclusive rights to multi-allergy oral product ImmunoBON
  • VLP-based Peanut product Phase I trial due to commence in 2021

Manuel Llobet, CEO at Allergy Therapeutics, stated: “The robust, all-round performance of the business this year has shown the key qualities of Allergy Therapeutics, with strong financial results, a fast response to the COVID-19 challenge and continued development and expansion of our commercial portfolio and pipeline. These present new opportunities for us to strengthen our leadership in the allergy immunotherapy field and, longer-term, explore the broader immunology space, with the potential to deliver increased value to shareholders and the patients we serve.”

*Constant currency uses prior year weighted average exchange rates to translate current year foreign currency denominated revenue to give a year on year comparison excluding the effects of foreign exchange movements. See table in finance review for an analysis of revenue.

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

Analyst briefing and webcast today

Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore, Head of Communications and Market Development, will host a virtual presentation for analysts to provide an update on the Group, followed by a Q&A session, at 09.30am BST.

Dial-in details are:

Webcast link: https://www.lsegissuerservices.com/spark/AllergyTherapeutics/events/6b256adc-9c2f-4e00-985b-d90848ce4fd0

UK dial-in: +44 (0) 203 107 0289
US dial-in: +1 (918) 922 6506
Conference ID: 4299121

- ENDS -

For further information, please contact:

Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer

Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking

Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser

Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia

Notes for editors:
About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focused on the treatment and diagnosis of allergic disorders, including aluminium-free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.



Source: Allergy Therapeutics

2020 GlobeNewswire, Inc., source Press Releases

01/14ALLERGY THERAPEUTICS : Half Year Trading Update 2021 and Notice of Results
2020ALLERGY THERAPEUTICS : 2020 AGM Poll Vote Results
2020ALLERGY THERAPEUTICS : Notice of Meeting
2020ALLERGY THERAPEUTICS :  Allergy Therapeutics plc Preliminary Results for the yea..
2020ALLERGY THERAPEUTICS : Block listing six monthly return
2020ALLERGY THERAPEUTICS : welcomes European Academy of Allergy and Clinical Immunol..
2020ALLERGY THERAPEUTICS : Half-year Report
2019ALLERGY THERAPEUTICS : Allergy Therapeutics announces update to Grass MATA MPL p..
2019ALLERGY THERAPEUTICS : Result of Annual General Meeting
More news
Sales 2021 83,4 M 114 M 114 M
Net income 2021 -4,55 M -6,19 M -6,19 M
Net cash 2021 29,5 M 40,2 M 40,2 M
P/E ratio 2021 -29,2x
Yield 2021 -
Capitalization 125 M 170 M 170 M
EV / Sales 2021 1,14x
EV / Sales 2022 1,20x
Nbr of Employees -
Free-Float 13,8%
Duration : Period :
Allergy Therapeutics plc Technical Analysis Chart | AGY | GB00B02LCQ05 | MarketScreener
Technical analysis trends ALLERGY THERAPEUTICS PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 5
Average target price 50,00 GBX
Last Close Price 19,50 GBX
Spread / Highest target 259%
Spread / Average Target 156%
Spread / Lowest Target 79,5%
EPS Revisions
Managers and Directors
Manuel Llobet Chief Executive Officer & Executive Director
Peter Sinclair Jensen Non-Executive Chairman
Bev Lees Group Director-Operations
Nicolas Alexander Ulrich Wykeman Chief Financial Officer & Executive Director
Murray Skinner Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993